PMID- 33374342
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210218
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 9
IP  - 1
DP  - 2020 Dec 24
TI  - Interferon-alpha-Induced Dendritic Cells Generated with Human Platelet Lysate Exhibit 
      Elevated Antigen Presenting Ability to Cytotoxic T Lymphocytes.
LID - 10.3390/vaccines9010010 [doi]
LID - 10
AB  - Given the recent advancements of immune checkpoint inhibitors, there is 
      considerable interest in cancer immunotherapy provided through dendritic cell 
      (DC)-based vaccination. Although many studies have been conducted to determine 
      the potency of DC vaccines against cancer, the clinical outcomes are not yet 
      optimal, and further improvement is necessary. In this study, we evaluated the 
      potential ability of human platelet lysate (HPL) to produce interferon-alpha-induced 
      DCs (IFN-DCs). In the presence of HPL, IFN-DCs (HPL-IFN-DCs) displayed high 
      viability, yield, and purity. Furthermore, HPL-IFN-DCs displayed increased CD14, 
      CD56, and CCR7 expressions compared with IFN-DCs produced without HPL; 
      HPL-IFN-DCs induced an extremely higher number of antigen-specific cytotoxic T 
      lymphocytes (CTLs) than IFN-DCs, which was evaluated with a human leukocyte 
      antigen (HLA)-restricted melanoma antigen recognized by T cells 1 (MART-1) 
      peptide. Additionally, the endocytic and proteolytic activities of HPL-IFN-DCs 
      were increased. Cytokine production of interleukin (IL)-6, IL-10, and tumor 
      necrosis factor (TNF)-alpha was also elevated in HPL-IFN-DCs, which may account for 
      the enhanced CTL, endocytic, and proteolytic activities. Our findings suggest 
      that ex-vivo-generated HPL-IFN-DCs are a novel monocyte-derived type of DC with 
      high endocytic and proteolytic activities, thus highlighting a unique strategy 
      for DC-based immunotherapies.
FAU - Date, Ippei
AU  - Date I
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku 920-0293, Japan.
FAU - Koya, Terutsugu
AU  - Koya T
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku 920-0293, Japan.
AD  - Center for Regenerative Medicine, Kanazawa Medical University Hospital, Uchinada, 
      Kahoku 920-0293, Japan.
FAU - Sakamoto, Takuya
AU  - Sakamoto T
AUID- ORCID: 0000-0003-2519-4510
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku 920-0293, Japan.
AD  - Center for Regenerative Medicine, Kanazawa Medical University Hospital, Uchinada, 
      Kahoku 920-0293, Japan.
FAU - Togi, Misa
AU  - Togi M
AUID- ORCID: 0000-0002-7424-4548
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku 920-0293, Japan.
AD  - Center for Regenerative Medicine, Kanazawa Medical University Hospital, Uchinada, 
      Kahoku 920-0293, Japan.
FAU - Kawaguchi, Haruhiko
AU  - Kawaguchi H
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku 920-0293, Japan.
FAU - Watanabe, Asuka
AU  - Watanabe A
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku 920-0293, Japan.
FAU - Kato, Tomohisa Jr
AU  - Kato T Jr
AD  - Medical Research Institute, Kanazawa Medical University, Uchinada, Kahoku 
      920-0293, Japan.
FAU - Shimodaira, Shigetaka
AU  - Shimodaira S
AUID- ORCID: 0000-0002-6612-6912
AD  - Department of Regenerative Medicine, Kanazawa Medical University, Uchinada, 
      Kahoku 920-0293, Japan.
AD  - Center for Regenerative Medicine, Kanazawa Medical University Hospital, Uchinada, 
      Kahoku 920-0293, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201224
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC7823331
OTO - NOTNLM
OT  - cytotoxic T lymphocyte
OT  - dendritic cells
OT  - endocytosis
OT  - human platelet lysate
OT  - immunotherapy
OT  - proteolytic activity
OT  - tumor-associated antigens
OT  - vaccine
COIS- All authors, except for S.S., T.K., T.S., and M.T., declare no conflicts of 
      interest. S.S., T.K., T.S., and M.T. evaluated DCO-K serum-free medium (Nissui 
      Pharmaceutical Co., Ltd.) for the DC culture. Kanazawa Medical University 
      concludes a collaborative investigation contract with Nissui Pharmaceutical Co., 
      Ltd. The funders had no role in the design of the study; in the collection, 
      analyses, or interpretation of data; in the writing of the manuscript, or in the 
      decision to publish the results.
EDAT- 2020/12/31 06:00
MHDA- 2020/12/31 06:01
PMCR- 2020/12/24
CRDT- 2020/12/30 01:01
PHST- 2020/11/25 00:00 [received]
PHST- 2020/12/21 00:00 [revised]
PHST- 2020/12/21 00:00 [accepted]
PHST- 2020/12/30 01:01 [entrez]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2020/12/31 06:01 [medline]
PHST- 2020/12/24 00:00 [pmc-release]
AID - vaccines9010010 [pii]
AID - vaccines-09-00010 [pii]
AID - 10.3390/vaccines9010010 [doi]
PST - epublish
SO  - Vaccines (Basel). 2020 Dec 24;9(1):10. doi: 10.3390/vaccines9010010.